{"id":"NCT03526861","sponsor":"LEO Pharma","briefTitle":"Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-19","primaryCompletion":"2020-04-15","completion":"2021-03-16","firstPosted":"2018-05-16","resultsPosted":"2021-10-29","lastUpdate":"2025-03-11"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"DRUG","name":"Placebos","otherNames":["Placebo"]}],"arms":[{"label":"Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA","type":"EXPERIMENTAL"},{"label":"Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB","type":"EXPERIMENTAL"},{"label":"Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA","type":"EXPERIMENTAL"},{"label":"Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB","type":"EXPERIMENTAL"},{"label":"Placebo initial-> Placebo maintenance","type":"EXPERIMENTAL"},{"label":"Tralokinumab (Dose1) initial-> Open-label tralokinumab","type":"EXPERIMENTAL"},{"label":"Tralokinumab (Dose2) initial-> Open-label tralokinumab","type":"EXPERIMENTAL"},{"label":"Placebo initial-> Open-label tralokinumab","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\nTo evaluate the efficacy of subcutaneous (SC) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to \\<18 years) with moderate-to-severe AD.\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health-related quality of life compared with placebo.\n\nTo investigate the safety, immunogenicity, and tolerability of SC administration of tralokinumab compared with placebo when used to treat adolescent subjects (age 12 to \\<18 years) with moderate-to-severe AD.","primaryOutcome":{"measure":"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Initial Treatment Period - Tralokinumab 300 mg Q2W","deltaMin":17,"sd":null},{"arm":"Initial Treatment Period - Tralokinumab 150 mg Q2W","deltaMin":21,"sd":null},{"arm":"Initial Treatment Period - Placebo","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":87,"countries":["United States","Australia","Belgium","Canada","France","Germany","Japan","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["37074705","40879371","40721559","40555305","35671038"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":97},"commonTop":["Viral upper respiratory tract infection","Dermatitis atopic","Upper respiratory tract infection","Headache","Injection site reaction"]}}